<DOC>
	<DOCNO>NCT01604889</DOCNO>
	<brief_summary>The study design include open-label , dose escalation phase follow blind , randomized phase , combine INCB024360 ( oral IDO1 inhibitor ) approve therapy compare approve therapy plus placebo metastatic melanoma patient .</brief_summary>
	<brief_title>A Phase 1/2 Randomized , Blinded , Placebo Controlled Study Ipilimumab Combination With INCB024360 Placebo Subjects With Unresectable Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject , age 18 year older unresectable metastatic melanoma . A life expectancy &gt; 12 week . Laboratory range medical criterion meet , define within protocol . Subject may receive 1 prior regimen systematic treatment unresectable metastatic melanoma . For Phase 2 period study , Subjects must archival tumor tissue available collect prior 6 month accessible disease pretreatment , study biopsy . Pregnant nursing woman . Current investigational trial participation another investigational product subject receive anticancer medication within 21 day prior screen ( 6 week mitomycinC nitrosoureas . ) Subjects receive monoamine oxidase inhibitor ( MAOI ) ; subject ever Serotonin Syndrome receive one serotonergic drug . Subjects receive prior immune checkpoint inhibitor ( eg antiCTLA4 , antiPD1 , anti PDL1 others ) Grade 3 4 hepatotoxicity , immune colitis require infliximab , endocrine toxicity control replacement , Grade 4 immune adverse event ( AEs ) ocular toxicity Subjects protocolspecified active autoimmune process except vitiligo thyroiditis . Subjects concurrent condition would jeopardize safety safety subject compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Melanoma , Skin Cancer , Oncology</keyword>
</DOC>